Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd. develops, produces and markets specialty plasma-derived therapeutics and other biopharmaceutical products for rare and serious conditions. News about KMDA commonly covers financial results and guidance, commercial performance of products such as KAMRAB, GLASSIA, HEPAGAM, VARIZIG, WINRHO and CYTOGAM, and supply arrangements for blood-product markets.
Company updates also address plasma collection operations, including FDA-cleared facilities in Texas, product distribution activity, dividend policy and withholding-tax procedures for ordinary-share distributions. Kamada is traded on Nasdaq and the Tel Aviv Stock Exchange.
Kamada (NASDAQ: KMDA) declared a cash dividend of $0.17 (≈NIS 0.50) per share, totaling about $9.8 million, on its ordinary shares. The dividend, consistent with the company’s cash dividend policy, will be paid on September 17, 2026 to shareholders of record on August 27, 2026.
According to Kamada, the decision follows record-high financial results and a solid cash position for the first six months of 2026. The company will withhold tax under Israeli law and has applied for an Israel Tax Authority ruling on withholding for non-Israeli shareholders.
Kamada (NASDAQ: KMDA) reported record-high results for the first half and second quarter of 2026. Q2 revenues reached $54.9 million, up 23% year-over-year, with adjusted EBITDA of $14.1 million, a 26% margin, and net income of $9.3 million, up 26%.
First-half 2026 revenues were $100.2 million, up 13%, with adjusted EBITDA of $25.7 million (26% margin) and net income of $13.4 million, up 18%. Operating cash flow for the first six months rose to $17.8 million from $7.5 million. Kamada reaffirmed 2026 guidance of $200–$205 million in revenues and $50–$53 million in adjusted EBITDA, implying 12% and 23% year-over-year growth at midpoints.
The company signed a new three-year plasma supply agreement of approximately $50 million, expects initial sales in Q4 2026, and paid a cash dividend of $0.25 per share (about $14.4 million). Cash and short-term investments totaled $70.1 million as of June 30, 2026.
Kamada (NASDAQ: KMDA) announced that Chief Financial Officer Chaime Orlev will step down from his role effective December 31, 2026 to pursue other opportunities. The company has begun a search for his successor.
Orlev, who has served as CFO since 2017, will provide transitional support to the new appointee. According to Kamada, recent earnings announcements indicate the company is on a growth trajectory with a solid financial position, and leadership emphasized his contributions to Kamada’s growth and operations.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA) will release its financial results for the second quarter and first half ended June 30, 2026, before U.S. market open on Wednesday, August 12, 2026. Management will host a conference call that day at 8:30am Eastern Time to review the results.
Investors can join by phone via U.S., Israel, or international dial-in numbers using conference ID 13761830, or listen to a live webcast at the provided ViaVid link.
Kamada (NASDAQ: KMDA) announced a new three-year agreement to supply normal source plasma from its FDA-approved collection centers in Houston and San Antonio, Texas, to a leading biopharmaceutical company focused on plasma-derived therapies. The agreement is expected to generate approximately $50 million in revenue over three years, with initial commercial sales anticipated in the fourth quarter of 2026.
Each Texas center is designed for a planned capacity of about 50,000 liters of plasma per year at full capacity, covering both normal source and specialty plasma. According to Kamada, this supply agreement supports its vertical-integration strategy, aligns with its multi-year revenue growth objectives, and the expected Q4 2026 sales are already included in its current full-year revenue guidance.
Kamada (NASDAQ: KMDA; TASE: KMDA.TA) reported new data from an Investigator-Initiated Study of CYTOGAM (CMV immune globulin) in cytomegalovirus (CMV) high‑risk lung transplant recipients, presented as three posters at the 2026 ISHLT annual meeting in Toronto.
According to Kamada, retrospective clinical analyses suggested that patients who did not receive CMVIG prophylaxis had worse outcomes than those who did, and translational work showed less activated innate immune cells in CMVIG‑treated patients. A non‑clinical in‑vivo model indicated that CMVIG exposure blunted lung injury and improved mortality. Kamada noted these findings, together with a prior five‑year, 324‑patient retrospective study, may support increased CYTOGAM utilization as part of multimodality CMV prophylaxis in high‑risk lung transplant populations.
Kamada (NASDAQ: KMDA) received FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) rabies virus neutralization laboratory at its Beit Kama, Israel plant. The lab expands Anti-Rabies potency testing for KEDRAB and KAMRAB, Kamada’s leading franchise with 2025 sales over $70 million.
The RFFIT lab is part of Kamada’s Quality Control network, is among a limited number of global facilities able to run this gold-standard test, and was also approved by Health Canada and the Israeli Ministry of Health.
Kamada (NASDAQ:KMDA) reported Q1 2026 revenue of $45.2M, up 3% year-over-year, net income of $4.1M, up 4%, and adjusted EBITDA of $11.6M with a 26% margin.
The company reaffirmed 2026 guidance of $200M–$205M revenue and $50M–$53M adjusted EBITDA, highlighted FDA approval of its San Antonio plasma center, and paid a $0.25-per-share dividend totaling about $14.4M.
Kamada (NASDAQ: KMDA) will release first quarter 2026 financial results for the period ended March 31, 2026, before U.S. markets open on May 13, 2026. Management will host an investor conference call on May 13 at 8:30am ET and a live webcast will be available.
Dial-in numbers and conference ID 13760232 are provided for U.S., Israel, and international participants; the call will be webcast at the company's public webcast link.
Kamada (NASDAQ: KMDA) obtained an Israel Tax Authority ruling for its previously announced $0.25 per-share cash dividend (approximately $14.4 million), payable April 7, 2026 to shareholders of record March 23, 2026. The Company will withhold 25% initially; Treaty-state Nasdaq shareholders may apply for reduced withholding or exemption by May 9, 2026.
The Tax Agent is IBI Trust Management; full procedures, documentation requirements, and timing for refunds to eligible shareholders are specified in the Ruling.